Microbiome–Metabolome Crosstalk as a Driver of COVID-19 Severity
Medical Sciences · 17.02.2026 · 14 (1) · 97
DOI: 10.3390/medsci14010097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 17.02.2026. Verfasst von Patricia Diez-Echave und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain. Hauptthemen laut MEDLINE: COVID-19, Metabolome, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Andalusian Health Service, Government of Andalucia.
Abstract (Originalsprache)
Background
COVID-19, caused by SARS-CoV-2, exhibits highly variable severity, from mild symptoms to respiratory failure and multiorgan dysfunction. Traditional risk factors incompletely explain this heterogeneity, highlighting the potential role of gut microbiota and host metabolomics in modulating immune responses.
Methods
Thus, this study investigates how gut microbiota variations are associated with plasma metabolite profiles in COVID-19, exploring relationships between microbial and metabolic signatures and disease severity and potential therapeutic targets. In a prospective cohort of 55 patients, stool and plasma samples were analyzed using 16S rRNA sequencing and untargeted LC-HRMS metabolomics.
Results
Severe COVID-19 was associated with reduced microbial diversity and enrichment of pro-inflammatory taxa, including Prevotella, Alistipes, Dialister, and Lachnoclostridium, whereas mild cases showed higher abundance of protective commensals such as Bacteroides, Faecalibacterium, and Blautia. Metabolomic profiling revealed alterations in bile acids, unsaturated fatty acids, tryptophan, and inositol phosphate pathways. Notably, linoleate levels were elevated in severe cases, showing correlations with pro-inflammatory microbes, while acylcarnitines and inositol derivatives were enriched in mild disease. Predictive functional analysis suggested that severe-associated microbes showed enhanced amino acid catabolism, oxidative glucose metabolism, and xenobiotic degradation, which may be linked to host inflammation.
Conclusions
These findings highlight associations between gut microbiota composition, microbial metabolism, and circulating metabolites in COVID-19 severity. Identified microbial and metabolomic signatures may represent potential candidates to be considered biomarkers and therapeutic targets to modulate disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
- Centro de Salud Las Gabias, Distrito Granada-Metropolitano, 18012 Granada, Spain.
- Centro de Salud "Salvador Caballero", Distrito Granada-Metropolitano, 18012 Granada, Spain.
- Servicio Microbiología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
- Servicio Microbiología, Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain.
ORCID-Profile: Patricia Diez-Echave, María Jesús Rodríguez-Sojo, Antonio Jesús Ruiz-Malagon, José Alberto Molina-Tijeras, Emilio Mota, Fernando Cobo, Federico García, Manuel Colmenero-Ruiz, María Elena Rodríguez-Cabezas, Emilio Fernandez-Varón, José Pérez Del Palacio, Javier Martin, Jorge García-García, Rocío Morón, Alba Rodríguez-Nogales, Julio Gálvez
Förderung
- Andalusian Health Service
- Government of Andalucia
Zitieren
APA
Diez-Echave, P., Rodríguez-Sojo, M. J., Martin-Castaño, B., Hidalgo-García, L., Ruiz-Malagon, A. J., Molina-Tijeras, J. A., Romero, A. R., Martínez-Zaldívar, M., Mota, E., Cobo, F., Alvarez-Estevez, M., García, F., Morales-García, C., Merlos, S., García-Flores, P., Colmenero-Ruiz, M., Nuñez, M., Ruiz-Sancho, A., Rodríguez-Cabezas, M. E., …, & Gálvez, J. (2026). Microbiome–Metabolome Crosstalk as a Driver of COVID-19 Severity. Medical Sciences, 14(1), 97. https://doi.org/10.3390/medsci14010097
Vancouver
Diez-Echave P, Rodríguez-Sojo MJ, Martin-Castaño B, Hidalgo-García L, Ruiz-Malagon AJ, Molina-Tijeras JA, et al. Microbiome–Metabolome Crosstalk as a Driver of COVID-19 Severity. Medical Sciences. 2026;14(1):97. doi:10.3390/medsci14010097
BibTeX
@article{DiezEchave2026,
author = {Diez-Echave, Patricia and Rodríguez-Sojo, María Jesús and Martin-Castaño, Benita and Hidalgo-García, Laura and Ruiz-Malagon, Antonio Jesús and Molina-Tijeras, José Alberto and Romero, Anaïs Redruello and Martínez-Zaldívar, Margarita and Mota, Emilio and Cobo, Fernando and Alvarez-Estevez, Marta and García, Federico and Morales-García, Concepción and Merlos, Silvia and García-Flores, Paula and Colmenero-Ruiz, Manuel and Nuñez, María and Ruiz-Sancho, Andrés and Rodríguez-Cabezas, María Elena and Gallego, Ángel Carazo and Fernandez-Varón, Emilio and Pérez Del Palacio, José and Martin, Javier and García-García, Jorge and Morón, Rocío and Rodríguez-Nogales, Alba and Gálvez, Julio},
title = {Microbiome–Metabolome Crosstalk as a Driver of COVID-19 Severity},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {1},
pages = {97},
doi = {10.3390/medsci14010097}
}
EUVIMED